Delivery Order SPE2DB20D1100-SPE2DB25FE0C9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,123.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count package) on August 1, 2025, with an ultimate completion date of August 22, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, meaning it was competitively awarded. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this...
- The Defense Logistics Agency awarded a delivery order valued at $8,118.08 to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on August 13, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ibrance 75 mg capsules (21-count packages) with a ceiling value of $8,123.96. This firm fixed-price delivery order, with an ultimate completion date of August 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The award is...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Ibrance 75 mg capsules. The contract, valued at $15,595.70, has an ultimate completion date of April 10, 2024. AmerisourceBergen Drug Corp previously held an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ibrance 100 mg capsules (21-count packaging) at a ceiling value of $8,122.48 under a firm fixed-price contract. This is a non-set-aside competitive award with a completion date of September 2, 2025, and represents a child contract under AmerisourceBergen's larger contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $16,244.96 to AmerisourceBergen Drug Corp for the supply of Ibrance 100 mg capsules (21-count) on August 5, 2025, with an ultimate completion date of August 26, 2025. This firm fixed price, non-set-aside contract reflects a routine pharmaceutical procurement to support federal medical supply needs. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,122.48 on August 12, 2025, for the supply of Ibrance 100 mg tablets (7-unit package). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 3, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ibrance 125 mg capsules (21-count packages) under a firm fixed-price contract valued at $8,118.08, with completion scheduled for August 22, 2025. This non-set-aside, competitively awarded delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor within the DLA's medical supply chain. The product will be delivered to...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ibrance 125 mg capsules (21-count units). This non-set-aside, competitively awarded contract specifies an ultimate completion date of August 28, 2025, and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $8,118.08 firm fixed price delivery order to AmerisourceBergen Drug Corp for Ibrance 125 mg capsules (21-count) on July 21, 2025, with an ultimate completion date of August 11, 2025. The contract, which carries no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a competitively awarded procurement from the company's existing pharmaceutical supply agreement...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE0C9Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,247.92 to AmerisourceBergen Drug Corp for the supply of Ibrance 75 mg capsules (21-count packaging) under a firm fixed price contract. The contract was competitively awarded without a set-aside designation and is scheduled for completion by September 3, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), a comprehensive $1 billion pharmaceutical supply vehicle valued through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen Drug Corp supplies brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains to support military and veteran healthcare systems. This delivery order for Ibrance, a oncology medication, represents a typical transaction within the company's extensive portfolio of federal pharmaceutical contracts with DLA. The firm fixed price structure and delivery order mechanism provide the Defense Health Agency and other federal customers with access to critical pharmaceutical products through an efficient procurement vehicle that has demonstrated AmerisourceBergen's capability to meet competitive federal requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.2k | 8/12/25 |